Jinarc

Tolvaptan, the active ingredient in Jinarc, is a vasopressin V2 receptor antagonist presented as a tablet for oral use. It is indicated for the management of autosomal dominant polycystic kidney disease (ADPKD) in adult patients, helping to slow cyst growth and preserve kidney function.

GNH USA supplies Jinarc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for importers, ensuring reliable and timely delivery across global markets.

Tolvaptan is used to manage autosomal dominant polycystic kidney disease, a genetic disorder affecting kidney cyst formation.

- Autosomal dominant polycystic kidney disease: slows cyst growth and helps preserve kidney function.

Tolvaptan may cause a range of adverse reactions.

Common Side Effects: - Thirst: increased sensation of needing fluids. - Polyuria: frequent urination. - Dry mouth: reduced salivary flow. - Increased urination volume: larger urine output.

Serious or Rare Side Effects: - Hepatic injury: elevated liver enzymes or liver failure. - Severe dehydration: excessive fluid loss leading to low blood pressure. - Hypernatremia: high blood sodium concentration.

Before initiating Tolvaptan therapy, several safety considerations should be observed.

- Liver monitoring: perform baseline and periodic liver function tests. - Hydration status: ensure adequate fluid intake to prevent dehydration. - Renal function: assess kidney function prior to use. - Concomitant hepatotoxic drugs: avoid or use with caution. - Pregnancy and lactation: contraindicated unless benefits outweigh risks. - Store below 25°C: keep in the original packaging, protect from moisture.

Tolvaptan can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase Tolvaptan exposure. - High‑dose diuretics combined with Tolvaptan: risk of severe dehydration. - Other V2 receptor antagonists: additive effect on water excretion.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): may raise plasma levels. - NSAIDs: potential impact on renal function. - Lithium: increased risk of lithium toxicity. - Warfarin: possible alteration of anticoagulant effect. - Rifampin: may reduce Tolvaptan concentrations.